**Early levels of GFAP and NF-L in predicting the outcome of mild TBI**

Iftakher Hossain, MD1, 2, 3, Mehrbod Mohammadian, MSc2, 3, Riikka S.K. Takala, MD, PhD2, 4, Olli Tenovuo, MD, PhD2, 3, Linnéa Lagerstedt, PhD5, Henna Ala-Seppälä, MD2, 3, Janek Frantzén MD, PhD1, 3, Mark van Gils, PhD6, Peter Hutchinson, MD, PhD7, Ari J. Katila, MD2, 4, Henna-Riikka Maanpää, MD1, 2, 3, David K. Menon MD, PhD8,Virginia F. Newcombe, MD, PhD8, Jussi Tallus, MD2, 3, 9, Kevin Hrusovsky, BSME, MBA10, David H. Wilson, PhD10, \*Kaj Blennow, MD, PhD11, 12, \*Jean-Charles Sanchez, PhD5, \*Henrik Zetterberg, MD, PhD11, 12, 13, 14, \*Jussi P. Posti, MD, PhD1, 2, 3

\*These authors contributed equally to this work

**Names of Departments and Institutions:** 1Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Finland; 2Turku Brain Injury Centre, Turku University Hospital, Finland; 3Department of Neurology, University of Turku, Finland; 4Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Finland; 5Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland; 6VTT Technical Research Centre of Finland Ltd., Tampere, Finland; 7Department of Clinical Neurosciences, Neurosurgery Unit, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom; 8Division of Anaesthesia, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom; 9Department of Radiology, Turku University Hospital, Turku, Finland; 10Quanterix Corporation, Lexington, MA, USA; 11Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; 12Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; 13Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; 14UK Dementia Research Institute at UCL, University College London, London, UK

**Corresponding author:** Dr. Iftakher Hossain, ifthos@utu.fi, +358 2 313 0282 (tel), +358 2 313 3052 (fax), Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, P.O. Box 52, FI-20521 Turku, Finland

**Running title:** GFAP and NF-L in mild TBI

**Key words:** 1) traumatic brain injury, 2) GFAP, 3) NF-L, 4) outcome

**Funding:** This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), Integra EANS Research Grant (IH), University of Turku Graduate School funding (MM), Government’s Special Financial Transfer tied to academic research in Health Sciences (JPP, RSKT), and personal grants from Emil Aaltonen Foundation sr and Finnish Brain Foundation sr (JPP)

**Mailing address and contact information**

Iftakher Hossain, MD, [ifthos@utu.fi](mailto:ifthos@utu.fi)

Division of Clinical Neurosciences, Department of Neurosurgery, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3052

Mehrbod Mohammadian, MSc, [mehmoh@utu.fi](mailto:mehmoh@utu.fi)

Division of Clinical Neurosciences, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 9022

Riikka S.K. Takala, MD, PhD, [riikka.takala@gmail.com](mailto:riikka.takala@gmail.com)

Division of Clinical Neurosciences, Turku Brain Injury Centre, and Perioperative Services, Intensive Care Medicine and Pain Management, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3960

Olli Tenovuo, MD, PhD, [olli.tenovuo@tyks.fi](mailto:olli.tenovuo@tyks.fi)

Division of Clinical Neurosciences, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 9022

Linnéa Lagerstedt, PhD, [linnea.lagerstedt@unige.ch](mailto:linnea.lagerstedt@unige.ch)

Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, 24 rue du Général-Dufour 1211 Genève 4, Geneva, Switzerland

Tel: +41 22 379 00 00, Fax: +41 22 379 11 34

Henna Ala-Seppälä, MD, [hmalse@utu.fi](mailto:hmalse@utu.fi)

Division of Clinical Neurosciences, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 9022

Janek Frantzén MD, PhD, [janek.frantzen@tyks.fi](mailto:janek.frantzen@tyks.fi)

Division of Clinical Neurosciences, Department of Neurosurgery, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3052

Mark van Gils, PhD, [mark.vanGils@vtt.fi](mailto:mark.vanGils@vtt.fi)

VTT Technical Research Centre of Finland Ltd. Tekniikankatu 11, 33101, Tampere, Finland

Tel: +358 20 722 3342, Fax: +358 20 722 3499

Peter Hutchinson, MD, PhD, [pjah2@cam.ac.uk](mailto:pjah2@cam.ac.uk)

Department of Clinical Neurosciences, Neurosurgery Unit, University of Cambridge, Addenbrooke’s Hospital, Hills Road, CB2 0QQ, Cambridge, United Kingdom

Tel: +44 1223 336946, Fax: +44 1223 216926

Ari J. Katila, MD, [ajkatila@gmail.com](mailto:ajkatila@gmail.com)

Division of Clinical Neurosciences, Turku Brain Injury Centre, and Perioperative Services, Intensive Care Medicine and Pain Management, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3960

Henna-Riikka Maanpää, MD, [hrmaan@utu.fi](mailto:hrmaan@utu.fi)

Division of Clinical Neurosciences, Department of Neurosurgery, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3052

David K. Menon MD, PhD, [dkm13@wbic.cam.ac.uk](mailto:dkm13@wbic.cam.ac.uk)

Division of Anaesthesia, University of Cambridge, Addenbrooke’s Hospital, Hills Road, CB2 0QQ, Cambridge, United Kingdom

Tel: +44 1223 217889, Fax: +44 1223 217887

Virginia F. Newcombe, MD, PhD, [vfjn2@cam.ac.uk](mailto:vfjn2@cam.ac.uk)

Division of Anaesthesia, University of Cambridge, Addenbrooke’s Hospital, Hills Road, CB2 0QQ, Cambridge, United Kingdom

Tel: +44 1223 217889, Fax: +44 1223 217887

Jussi Tallus, MD, [jptall@utu.fi](mailto:jptall@utu.fi)

Division of Clinical Neurosciences, Turku Brain Injury Centre, Department of Neurology, and Department of Radiology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 9022

Kevin Hrusovsky, BSME, MBA, [khrusovsky@quanterix.com](mailto:khrusovsky@quanterix.com)

Quanterix Corporation, 113 Hartwell Avenue Lexington, MA 02421 USA

Tel: +1 (617) 301-9400, Fax: +82-31-628-3007

David H. Wilson, PhD, [dwilson@quanterix.com](mailto:dwilson@quanterix.com)

Quanterix Corporation, 113 Hartwell Avenue Lexington, MA 02421 USA

Tel: +1 (617) 301-9400, Fax: Fax: +82-31-628-3007

Kaj Blennow, MD, PhD, [kaj.blennow@neuro.gu.se](mailto:kaj.blennow@neuro.gu.se)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Blå Stråket 15, Vån 3 SU/Sahlgrenska, 413 45 Göteborg, Sweden  
Tel: +46 31 3431791, Fax: +358 3 311 64355  
Jean-Charles Sanchez, PhD, [jean-charles.sanchez@unige.ch](mailto:jean-charles.sanchez@unige.ch)

Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, 24 rue du Général-Dufour 1211 Genève 4, Geneva, Switzerland

Tel: +41 22 379 00 00, Fax: +41 22 379 11 34

Henrik Zetterberg, MD, PhD, [henrik.zetterberg@clinchem.gu.se](mailto:henrik.zetterberg@clinchem.gu.se)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden  
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden UK Dementia Research Institute at University College London, London, United Kingdom Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom

Blå Stråket 15, Vån 3 SU/Sahlgrenska, 413 45 Göteborg, Sweden   
Tel: +46 (0)76-867 26 47, Fax: Fax: +358 3 311 64355

Jussi P. Posti, [jussi.posti@utu.fi](mailto:jussi.posti@utu.fi)

Division of Clinical Neurosciences, Department of Neurosurgery, Turku Brain Injury Centre, and Department of Neurology, University of Turku and Turku University Hospital, Hämeentie 11, FI-20521 Turku, Finland

Tel: +358 2 313 0000, Fax: +358 2 313 3052

**ABSTRACT**

The purpose of this study was to correlate the early levels of glial fibrillary acidic protein (GFAP) and neurofilament light protein (NF-L) with outcome in patients with mild traumatic brain injury (mTBI). 107 patients with mTBI [Glasgow Coma Scale (GCS) ≥13] having the blood samples for GFAP and NF-L available within 24 hrs from arrival were included. Patients with mTBI were divided into computed tomography (CT)-positive and CT-negative groups. Glasgow Outcome Scale extended (GOSE) was used to assess the outcome. Outcomes were defined as complete (GOSE 8) vs. incomplete (GOSE <8), and favorable (GOSE 5-8) vs. unfavorable (GOSE 1-4). GFAP and NF-L concentrations in blood were measured using ultrasensitive single molecule array technology. Patients with incomplete recovery had significantly higher levels of NF-L compared to those with complete recovery (p=0.005). The levels of GFAP and NF-L were significantly higher in patients with unfavorable outcome than in patients with favorable outcome (p=0.002 for GFAP and p <0.001 for NF-L). For predicting favorable outcome, the area under the ROC curve for GFAP and NF-L was 0.755 and 0.826, respectively. In a multivariate logistic regression model, the level of NF-L was still a significant predictor for complete recovery (OR=1.008, 95%CI, 1.000-1.016). Moreover, the level of NF-L was a significant predictor for complete recovery in CT-positive patients (OR=1.009, 95%CI, 1.001-1.016). The early levels of GFAP and NF-L are significantly correlated with the outcome in patients with mTBI. The level of NF-L within 24 hrs from arrival has a significant predictive value in mTBI also in a multivariate model.

## Introduction

Of all subjects with traumatic brain injury (TBI), mild TBIs (mTBI) comprise 80-90%, a number that is believed to be an underestimate as it only includes those presenting to the emergency departments.1,2 Currently, there is no unanimous definition of mTBI,2 and current prediction models for mTBI have shown fairly poor performance.3 Computed tomography (CT), a standard tool to assess acute TBI, is insensitive at detecting microbleeds and is unable to detect either diffuse axonal injury (DAI)4 or metabolic disturbances5, which are the most common mechanisms of TBI. Many patients with mTBI suffer from neurological, cognitive and behavioural symptoms for days – weeks, and even one in four patients still have residual symptoms after one year.6

Brain injury biomarkers provide objective measures of pathophysiological events following a TBI and could reflect TBI severity, thus aiding the clinician in predicting outcome.7 In case of mTBI, blood biomarkers could be useful in evaluating the risk for prolonged problems.8,9,10 S100 calcium binding protein (S100-B), which is principally expressed in glial cells, has been the most studied biomarker in mTBI.11,12,13,14 Regrettably, it neither seems to be a useful prognosticator of TBI outcome, partly due to extracerebral expression;15,16,17 nor has it been able to discriminate patients who will develop prolonged or persistent symptoms.18

Glial fibrillary acidic protein (GFAP) is also an indicator of glial damage and almost exclusively found in the CNS, is a monomeric intermediate filament protein located in glial skeleton.19,20,21 Several papers have reported the potential utility of this biomarker in predicting clinical outcome in TBI.17,22,23,24,25

Neurofilament light (NF-L) protein is the most abundant of the three neurofilament proteins26 and is mainly expressed in the long myelinated white-matter axons.27,28 One study showed a very marked increase in the serum levels of NF-L in patients with severe TBI, with gradually increasing levels up to 10-12 days post trauma, and the levels predicted clinical outcome at several time-points, also at admission.29 Another study showed that the levels of NF-L 7-10 days after bout in amateur boxers correlated with the number of head impacts during the match, and the levels were elevated also in professional hockey players suffering from symptoms following repetitive mTBI.30 The levels of NF-L in cerebrospinal fluid (CSF) were able to discriminate two groups of contact sports athletes, those with rapidly resolving from prolonged concussion symptoms.31

The aim of the current study was to correlate the levels of GFAP and NF-L during the first 24 hours after admission with outcome in patients with mTBI, in order to find out their potential for clinical use in assessing mTBI.

## Methods

### **Study population**

This prospective study was part of the EU-funded TBIcare (Evidence-based Diagnostic and Treatment Planning Solution for Traumatic Brain Injuries) project. We recruited 107 patients with mTBI [Glasgow Coma Scale (GCS) ≥13] having blood samples available within 24 hours from the arrival to the emergency department (ED) of Turku University Hospital, Finland.

Inclusion criteria were: GCS ≥13, age ≥18 years, clinical diagnosis of TBI and indications for acute head CT according to NICE criteria (<http://www.nice.org.uk/guidance/cg176>).

Exclusion criteria were: age <18 years, blast-induced or penetrating injury, chronic subdural hematoma, inability to live independently due to pre-existing brain disease, TBI or suspected TBI not needing head CT, more than 2 weeks from the injury, not living in the district thereby preventing follow-up visits, not speaking native language, or no consent received.

The ethical review board of Hospital District of South-West Finland approved the study protocol. All patients or their next of kin were informed about the study in both oral and written forms and a written informed consent was obtained.

### **Analysis of GFAP and NF-L**

Plasma GFAP and NF-L levels were measured using the Human Neurology 4-Plex A assay (N4PA) on an HD-1 Single molecule array (Simoa) instrument according to instructions from the manufacturer (Quanterix, Lexington, MA). The measurements were performed in one round of experiments using one batch of reagents by board-certified laboratory technicians who were blinded to clinical data. Quality control (QC) samples were analyzed in each run, with coefficients of variations (CV) of 3.1% at 113 pg/mL and 3.8% at 86 pg/mL for GFAP, and 4.4% at 13.9 pg/mL and 6.1% at 7.1 pg/mL for NF-L.

### **TBI severity and outcome grading**

GCS scores were assessed by paramedics at the scene of accident or during transport, and/or by an emergency physician at the time of admission. In assessing the severity, the lowest recorded post-resuscitation GCS was used.24,32 The overall injury severity of the patients was assessed using the Injury Severity Score (ISS).33 The duration of posttraumatic amnesia (PTA) was assessed at the outcome visit using the Rivermead method.34 Analysis of CT scans was conducted according to descriptive system proposed by Marshall et al.,35 where class 1 corresponds with normal CT, classes 2-4 diffuse injuries, and classes 5-6 CTs with mass lesions.

**Outcome**

The outcome was assessed 6-12 months after the injury using the Extended Glasgow Outcome Scale (GOSE).36 Outcomes were defined as complete recovery (GOSE 8), incomplete recovery (GOSE <8), favorable outcome (GOSE 5-8), and unfavorable outcome (GOSE 1-4). Rivermead Post Concussion Symptoms Questionnaire (RPCSQ)37 was used to assess the presence and severity of mTBI-related symptoms.

**Statistical analyses**

Demographics of the subjects are presented as mean ±SD. Normality of distribution of biomarkers levels was assessed with the Kolmogorov-Smirnov test and by visually inspecting data histograms. As the levels of GFAP and NF-L were not normally distributed, nonparametric tests were used in the statistical analyses. Data are presented as medians and interquartile range [IQR]. Correlations between the levels of biomarkers and the outcomes were analyzed with Spearman rank correlation coefficient. Pearson’s correlation coefficient was used to evaluate the correlation between biomarker levels with age and gender. Mann-Whitney U test was used to compare the levels of biomarkers between the outcome groups. Multivariate logistic regression analysis was done to study the prognostic ability of the biomarkers to predict the dichotomized outcomes. The regression analysis was done including the following variables: age, ISS, worst GCS, Marshall score, PTA, time from injury to blood sampling, pupillary reactivity, and the levels of GFAP and NF-L. Marshall score and pupil reactivity were used as categorical variables. Marshall class I denoting CT-negative finding and reactive pupils were used as reference categories in multivariate logistic regression. GFAP and NF-L were used in the multivariate logistic regression models independently with the other variables and together in the same models. Area under the receiver operating characteristic (ROC) curve (AUC) was also used to evaluate the prognostic ability of the biomarkers. AUC of 0.8 to 1.0 was considered very good; AUC of 0.7 to 0.8 was considered adequate; and AUC of 0.5 to 0.7 was considered poor.21 A p value <0.05 was considered statistically significant. Cut-off values for the prediction of dichotomized outcomes were defined using the ROC curve at the sensitivity >90%. Pearson’s correlation coefficient was used to assess the correlation between the levels of GFAP and NF-L in the whole study population. Besides this, the correlation in the different outcome groups: complete, incomplete, favorable, and unfavorable outcome were also measured. For the data analyses, IBM SPSS Statistics 22 (IBM Corp, Armonk, New York) and MATLAB R2015b (Math Works, Natick, Massachusetts) were used. Additionally, panels of biomarkers were generated using PanelomiX software38 based on their best cut-off values. Panels of biomarkers were used to assess the performance of combination of biomarkers to discriminate complete and incomplete recovery, as well as favorable and unfavorable outcome. Cut-off values were selected for a sensitivity of >90%.

**Results**

**Demographics, Injury Severities, CT imaging and Outcomes**

One-hundred-and-seven patients with mTBI were recruited, with a mean age of 47.6 ±20.2 years and most of them being male (n=73, 68.2%). 55 patients (51.4%) were CT-positive, and 52 (48.6%) were CT-negative. Patient characteristics are shown in Table 1. For 105 (98.1%) patients the GOSE scores were available. Regarding the outcome, 37 patients (34.6%) had complete recovery, 68 patients (63.5%) had incomplete recovery, 90 patients (84.1%) had favorable outcome, 15 patients (14%) had unfavorable outcome, and the mortality was 3.7% (n=4).

**GFAP and outcome**

The levels of GFAP were compared between patients with complete recovery vs. incomplete recovery, and favorable outcome vs. unfavorable outcome (Figures 1A and 1B). The levels were not significantly different between patients with complete (median, 612pg/mL; interquartile range [IQR], 1996pg/mL) and incomplete recovery (median, 1467pg/mL; IQR, 6453pg/mL). The levels of GFAP (median, 4867pg/mL; IQR, 24667pg/mL) were significantly higher in patients with unfavorable outcome than in patients with favorable outcome (median, 875pg/mL; IQR, 2280pg/mL; p=0.002).

There was a significant negative correlation between the levels of GFAP and GOSE score (Spearman ρ=-0.25, p=0.010) (Table 2). GFAP could predict complete recovery, with an AUC of 0.598 (95%CI 0.489-0.706, p=0.099) and favorable outcome, with an AUC of 0.755 (95%CI 0.628-0.882, p=0.002) (Figures 2A and 2B).

*GFAP and outcome in CT-positive/negative mTBI*

When patients were divided into CT-positive and CT-negative subgroups, the levels of GFAP did not differ between the outcome groups nor did the levels correlate significantly with the outcome within these subgroups.

In a multivariate logistic regression model, GFAP was not able to predict outcome independently or together with NF-L.

**NF-L and outcome**

Patients with incomplete recovery had significantly higher levels of NF-L (median, 17pg/mL; IQR, 47pg/mL) compared to those with complete recovery (median, 11pg/mL; IQR, 10pg/mL; p=0.005). The levels of NF-L (median, 66pg/mL; IQR, 35pg/mL) were also significantly higher in patients with unfavorable outcome than in patients with favorable outcome (median, 13pg/mL; IQR, 13pg/mL; p<0.001) (Figures 1A and 1B). There was a significant negative correlation between the levels of NF-L and GOSE score (Spearman ρ=-0.382, p<0.001) (Table 2). NF-L could predict complete recovery, with an AUC of 0.665 (95%CI 0.561-0.768, p=0.005) and favorable outcome, with an AUC of 0.826 (95%CI 0.694-0.958, p<0.001) (Figures 2A and 2B). In a multivariate logistic regression model, the level of NF-L was a predictor for complete recovery (OR=1.008, 95%CI, 1.000-1.016) having GFAP in the model (Table 3). Furthermore, the level of NF-L was a statistically significant predictor for complete recovery in a multivariate logistic regression model (OR=1.006, 95%CI, 1.001-1.011).

*NF-L and outcome in CT-positive/negative mTBI*

Within the CT-negative mTBI subgroup, the levels of NF-L did not differ between the outcome groups, nor did the levels correlate significantly with the outcome. Within the CT-positive mTBI subgroup the patients with incomplete recovery had significantly higher levels of NF-L (median, 52pg/mL; IQR, 54pg/mL) compared to patients with complete recovery (median, 15pg/mL; IQR, 15pg/mL; p=0.007). Within the CT-positive mTBI subgroup, the levels of NF-L (median, 66pg/mL; IQR, 35pg/mL) were also significantly higher in patients with unfavorable outcome than in patients with favorable outcome (median, 20pg/mL; IQR, 41pg/mL; p=0.013).

Within the patients with CT-positive mTBI, there was a significant negative correlation between the levels of NF-L and GOSE score (Spearman ρ=-0.450, p=0.001). In this subgroup, NF-L could predict complete recovery, with an AUC of 0.750 (95%CI 0.593-0.908, p=0.007) and favorable outcome, with an AUC of 0.720 (95%CI 0.559-0.880, p=0.013). Furthermore, in CT-positive mTBI the level of NF-L was a significant predictor for complete recovery in a multivariate logistic regression model (OR=1.009, 95%CI 1.001-1.016).

**Cut-off values**

Cut-off values for GFAP and NF-L were derived from the ROC curves of full cohort for predicting complete recovery and favorable outcome. The minimum level of sensitivity was set to 90%.

For the prediction of complete recovery, the cut-off level of GFAP was 6438.05pg/mL with a sensitivity of 97% (95%CI, 86-100) and a specificity of 26% (95%CI, 68-99). For predicting favorable outcome, the cut-off value of GFAP was 12189.85pg/mL with a sensitivity of 92% (95%CI, 85-99) and a specificity of 47% (95%CI, 16-68).

For predicting complete recovery, the cut-off level of NF-L was 28.15pg/mL with a sensitivity of 94% (95%CI, 82-99) and a specificity of 44% (95%CI, 32-57). For predicting favorable outcome, the cut-off value of NF-L was 53.6pg/mL with a sensitivity of 90% (95%CI, 82-95) and a specificity of 67% (95%CI, 38-88) (eTable 4)

**Combination of GFAP + NF-L and outcome**

Using a combination of the two biomarkers with sensitivity set to >90% for complete recovery, the optimal sensitivity and specificity was 94.6% (95%CI, 86.5-100.0) and 47.1% (95%CI, 35.3-58.8), respectively (eFigure 3A), with GFAP and NF-L levels below 6438.05pg/mL and 28.15pg/mL, respectively.

When sensitivity was set to >90% for favorable outcome, the optimal sensitivity and specificity was 90.0% (95%CI, 83.3-95.6) and 86.7% (95%CI, 66.7-100.0), respectively (eFigure 3B), with GFAP and NF-L levels below 980.75pg/mL and 41.85pg/mL, respectively.

Correlation between the levels of GFAP and NF-L

Except for unfavorable outcome, the levels of GFAP and NF-L were significantly correlated. For the whole study population, Pearson’s r=0.635, p<0.0001. For favorable outcome, complete, and incomplete recovery, Pearson’s r=0.739, p<0.0001, Pearson’s r=0.995, p<0.0001, Pearson’s r=0.496, p<0.0001, respectively.

**Discussion**

We found that in this population and at this time-point of sampling, NF-L was useful in predicting favorable outcome, and to a lesser degree also complete recovery. Also, GFAP could predict favorable outcome adequately. Our most important finding is that for all patients with mTBI, in a multivariate logistic regression model including known outcome predictors and the level of GFAP, NF-L was a statistically significant predictor for complete recovery. Moreover, NF-L was an independent predictor for complete recovery in patients with CT-positive mTBI in a multivariate logistic regression model including the same clinical variables. A combination of these two biomarkers showed a higher sensitivity (94.6%) and specificity (47.1%) for predicting complete recovery compared to a single biomarker. This combination was also found to have a higher sensitivity (90.0%) and specificity (86.7%) for predicting favorable outcome compared to a single biomarker. Patients with incomplete recovery had significantly higher levels of NF-L than those with complete recovery. The levels of GFAP and NF-L were significantly higher in patients with unfavorable outcome than in patients with favorable outcome. There was also a strong negative correlation between the levels of GFAP and NF-L and outcome assessed with GOSE. Since GFAP and NF-L are expressed by different cell types and thus indicate different mechanisms of TBI, the fact that their correlation was weakest in those patients with unfavorable outcome supports the need to use a panel of biomarkers for reliable outcome prediction following mTBI.

Recently, our research group reported that in a cohort of patients with TBIs of all severities, the levels of GFAP on day 1 after the injury were higher in patients with incomplete recovery. The levels of GFAP on arrival day, day 1 and 2 were higher in patients with unfavorable outcome and also correlated negatively with GOSE. In addition, GFAP upon arrival was able to distinguish between favorable and unfavorable recovery.24 An earlier study reported that the levels of GFAP were lower in patients with favorable outcome than with unfavorable outcome within the first 12 hours of injury.21 One study demonstrated that elevated levels of GFAP on day 2 were able to predict mortality in patients with TBI,39 and another study found that the levels of GFAP were good predictors of outcome within 6 hours from TBI.40 In one study, GFAP breakdown products could poorly predict complete recovery, but predicted adequately favorable outcome.41 Interestingly, Metting et al. found that the levels of GFAP measured within 3 hours after injury could not predict complete recovery when outcome was assessed with GOSE at 6 months after mTBI,42 which may be related to the finding that GFAP levels appear to rise up to 16–24 h after the injury.43 In the TRACK-TBI study, where 83% of the study subjects were patients with mTBI, the levels of GFAP were not able to discriminate those with complete recovery from those with incomplete recovery.23

Two previous studies, including TBIs of all severities, have reported that GFAP is able to distinguish patients with favorable outcome from patients with unfavorable outcome.23,24 The TRACK-TBI investigators reported that the levels of GFAP could adequately discriminate favorable outcome from unfavorable outcome, with an AUC of 0.74 (95%CI, 0.61-0.87).23 Our earlier study reported that the levels of GFAP could adequately distinguish favorable outcome from unfavorable outcome, with an AUC of 0.723 (95%CI, 0.602-0.814) 24. The results from the present study are thus consistent with the aforementioned studies, with an AUC of 0.755 (95%CI 0.628-0.882). It has been suggested that combining several astroglia-derived markers may improve the predictive ability44.

NF-L has been reported to be a highly sensitive blood-based protein biomarker for severe TBI.29 The same group has also investigated the relationship between diffusion tensor imaging of DAI following a severe TBI and the levels of NF-L in the CSF, showing that the levels of NF-L could predict the degree of axonal injury as well as the outcome following TBI.28 A novel finding in our study is that the levels of NF-L were able to distinguish patients with complete recovery from incomplete recovery and favorable outcome from unfavorable outcome, not only in the whole population but also in patients with CT-positive mTBI. Although in earlier studies, the levels of NF-L were able to differentiate athletes with prolonged symptoms from those with rapid recovery following concussion,30,31 in our study neither the levels of NF-L nor GFAP correlated with the RPCSQ scores. However, the levels of NF-L correlated with the GOSE scores. By combining the levels of GFAP and NF-L we obtained better sensitivity and specificity compared to use of either biomarker alone.

Both biomarkers failed to predict recovery in CT-negative patients. This could potentially be due to inadequate statistical power – though there were approximately similar numbers of CT-positive and CT-negative patients in our cohort, the event rate for poor outcomes was lower in the latter group. However, it is also possible that the drivers of poorer outcome are different in CT-positive and negative groups, with outcome in the latter group driven more by host factors (such as education, premorbid psychological health, and coping strategies)45 rather than by structural injury that is detectable by blood biomarkers or structural neuroimaging.

Ultrasensitive single molecule array (Simoa) technology was used to measure the levels of these blood-based protein biomarkers, which is strength in our study. Simoa has been reported as more sensitive than conventional enzyme-linked immunosorbent assay (ELISA) or electro-chemiluminescence (ECL)-based assay.46 Another strength of our study is the considerable sample size in a well-characterized cohort.

The main limitation is that we did not have data for GFAP and NF-L available beyond 24 hrs after admission. Later levels could provide more information about the likelihood of recovery. The time from injury to sampling was variable, which may well influence the levels of these biomarkers, although this was tried to take into account as a covariate. A more precise knowledge of the kinetics of these biomarkers after a TBI would be needed to assess the clinical significance of various levels measured. Another limitation is that we did not have information about the duration of symptoms after the mTBI in those who had recovered before the outcome evaluation. It is also important to mention that our mTBI cohort does not represent typical general mTBI population, because only GCS was used to assess the severity and because there was a high percentage of patients with CT-positive findings, since they were more easily recruited due to hospital admission. The variability in assessing the GOSE, between 6 to 12 months after the injury, is a limitation that needs to be recognized. However, every patient was evaluated by the same experienced clinician. In addition, studies suggest that most who recover fully from a mTBI recover fairly quickly, and that the majority of those who are symptomatic at 6 months have not recovered at one year, either47. Yet, it is possible that some who were still symptomatic at 6 months might have recovered by one year, which potentially causes some uncertainty in the outcome evaluation. While based on all available data our patients had a minimum GCS of 13 or more, it should be noted that using other severity measures used in the literature PTA some might have had a more severe injury. Because we found the duration of PTA impossible to assess reliably in many patients, and because there is no generally accepted severity classification of imaging findings in TBI, we chose to use only GCS which gives the least uncertainty and is the most often used. When interpreting the results of our study one should note the quite large confidence intervals for the prognostic ability of these biomarkers, which is obviously due to the fairly small sample size, especially taking into consideration the large variability within mTBI. Although the percentage of those subjects who showed an unfavorable outcome after mTBI (15/107, 14%) is in line with the general concept of mTBI outcome, our results should be confirmed in larger materials.

Due to the complexity and individual variability of TBI, developing clinically useful biomarkers for this condition has proven to be a challenging task. This study shows that both GFAP and NF-L may be useful predictive biomarkers in mTBI, but because of the limitations discussed above, more studies are needed to clarify the useful time points as well as other potential limitations for their clinical use. These problems have been discussed in a recent systematic review48.

**Conclusions**

The early levels of GFAP and NF-L are significantly correlated with the outcome in patients with mTBI. The level of NF-L within 24 hrs from arrival has a significant predictive value in mTBI also in a multivariate model.

## Acknowledgement

This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), Integra EANS Research Grant (IH), University of Turku Graduate School funding (MM), Government’s Special Financial Transfer tied to academic research in Health Sciences (Finland) (JPP), Emil Aaltonen Foundation sr (JPP), Finnish Brain Foundation sr (JPP), and NIHR Research Fellowship (PJH). VFJN is funded by an Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship. HZ is a Wallenberg Academy Fellow and holds grants from the Swedish and European Research Councils. KB holds the Torsten Söderberg Professorship in Medicine, awarded by the Royal Swedish Academy of Sciences, and holds grants from the Swedish Research Council. The authors thank our research nurses Patricia Bertenyi and Satu Honkala for their valuable contribution to this study.

## Disclosures

**Iftakher Hossain** has no financial disclosures; **Mehrbod Mohammadian** has no financial disclosures; **Riikka S.K. Takala** has no financial disclosures. RSKT has received speakers fee from Abbott, Fresenius-Kabi, Orion and UCB, conference funding from Pfizer and Steripolar and is stockholder of Orion; **Olli Tenovuo** has no financial disclosures; **Linnéa Lagerstedt** has no financial disclosures; **Henna Ala-Seppälä** has no financial disclosures; **Janek Frantzén** has no financial disclosures; **Mark van Gils** has no financial disclosures; **Peter J. Hutchinson** has no financial disclosures; **Ari J. Katila** has no financial disclosures; **Henna-Riikka Maanpää** has no financial disclosures; **David K. Menon** reports collaborative research or consultancy agreements with GlaxoSmithKline Ltd; Ornim Medical; Shire Medical; Calico Inc; Pfizer Ltd; Pressura Ltd; Glide Pharma Ltd; NeuroTraumaSciences LLC; Lantasman AB; **Virginia F. Newcombe** has no financial disclosures; **Jussi Tallus** has no financial disclosures; **Kevin Hrusovsky** has no financial disclosures; **David H. Wilson** has no financial disclosures; **Jean-Charles Sanchez**  has no financial disclosures; **Henrik Zetterberg** has served at advisory boards for Roche Diagnostics, Eli Lilly and Wave, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg; **Kaj Blennow** has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg; **Jussi P. Posti** has no financial disclosures. JPP has received speaker’s fees from Orion corporation and Finnish Medical Association.

**References**

1. Faul, M., Xu, L., Wald, M. M., Coronado, V. G. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths 2002–2006. Atlanta (GA): US Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2010: 1–71.

2. Levin, H.S., and Diaz-Arrastia, R. (2015). Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancer Neurol 14, 506-17

3. Lingsma, H. F., Yue, J. K., Maas, A. I., Steyerberg, E. W., Manley, G. T., and TRACK-TBI Investigators. (2015). Outcome prediction after mild and complicated mild traumatic brain injury: external validation of existing models and identification of new predictors using the TRACK-TBI pilot study. J Neurotrauma 32, 83-94.

4. Mittl, R. L., Grossman, R. I., Hiehle, J. F., Hurst, R. W., Kauder, D. R., Gennarelli, T. A., and Alburger G. W. (1994). Prevalence of MR evidence of diffuse axonal injury in patients with mild head injury and normal head CT findings. AJNR Am J Neuroradiol 15, 1583-9.

5. Giza, C.C., and Hovda, D. A. (2014). The new neurometabolic cascade of concussion. Neurosurgery 75, 24-33.

6. McMahon, P., Hricik, A., Yue, JK., Puccio, A. M., Inoue, T., Lingsma, H. F., Beers, S. R., Gordon, W. A., Valadka, A. B., Manley, G. T., Okonkwo, D. O., and TRACK-TBI Investigators. (2014) Symptomatology and functional outcome in mild traumatic brain injury: results from the prospective TRACK-TBI study. J Neurotrauma 31, 26-33.

7. Maas, A. I., Stocchetti, N., and Bullock, R. (2008). Moderate and severe traumatic brain injury in adults. Lancet Neurol 7, 728-41.

8. Herrmann, M., Curio, N., Jost, S., Grubich, C., Ebert, A. D., Fork, M. L., and Synowitz, H. (2001). Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry 70, 95-100.

9. Bogoslovsky, T., Gill, J., Jeromin, A., Davis, C., and Diaz-Arrastia, R. (2016). Fluid Biomarkers of Traumatic Brain Injury and Intended Context of Use. Diagnostics (Basel) 6, pii: E37.

10. Wang, K. K., Yang, Z., Zhu, T., Shi, Y., Rubenstein, R., Tyndall, J. A., and Manley, G. T. (2018). An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 18,165-180.

11. Muller, K., Townend, W., Biasca, N., Unden, J., Waterloo, K., Romner, B., and Ingebrigtsen T. (2007). S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62,1452-6.

12. Zongo, D., Ribereau-Gayon, R., Masson, F., Laborey, M., Contrand, B., Salmi, L. R., Montaudon D, Beaudeux J. L, Meurin A, Dousset V, Loiseau H, and Lagarde E. (2012). S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 59, 209-18.

13. Egea-Guerrero, J. J., Revuelto-Rey, J., Murillo-Cabezas, F., Munoz-Sanchez, M. A., Vilches-Arenas, A., Sanchez-Linares, P., Domínguez-Roldán J. M, and León-Carrión J. (2012). Accuracy of the S100beta protein as a marker of brain damage in traumatic brain injury. Brain Inj 26, 76-82.

14. Jeter, C. B., Hergenroeder, G. W., Hylin, M. J., Redell, J. B., Moore, A. N., and Dash, P. K. (2013). Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma 30, 657-70.

15. Anderson, R. E., Hansson, L. O., Nilsson, O., Dijlai-Merzoug, R., and Settergren, G. (2001). High serum S100B levels for trauma patients without head injuries. Neurosurgery 48, 1255-8; discussion 1258-60.

16. Welch, R. D., Ayaz, S. I., Lewis, L. M., Unden, J., Chen, J. Y., Mika, V. H., Saville B., Tyndall J. A, Nash, M., Buki A., Barzo, P., Hack, D., Tortella, F. C., Schmid, K., Hayes, R. L., Vossough, A., Sweriduk, S. T., and Bazarian, J. J (2016). Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury. J Neurotrauma 33, 203-14.

17. Metting, Z., Wilczak, N., Rodiger, L. A., Schaaf, J. M., and van der Naalt, J. (2012). GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology 78, 1428-33.

18. Mercier, E., Tardif, P. A., Cameron, P.A., Batomen Kuimi, B.L., Émond, M., Moore, L., Mitra, B., Frenette, J., De Guise, E., Ouellet, M. C, Bordeleau, M., and Le Sage, N. (2018). Prognostic value of S-100B protein for prediction post-concussion syndrome after a mild traumatic brain injury: systemic review and meta-analysis. Journal of Neurotrauma 35, 609-622.

19. Eng, L. F., Vanderhaeghen, J. J., Bignami, A., and Gerstl, B. (1971). An acidic protein isolated from fibrous astrocytes. Brain Res 28, 351-4.

20. Missler, U., Wiesmann, M., Wittmann, G., Magerkurth, O., and Hagenstrom, H. (1999). Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 45, 138-41.

21. Zetterberg, H., Smith, DH., and Blennow, K. (2013) Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 9, 201-10.

22. Pelinka, L. E., Kroepfl, A., Leixnering, M., Buchinger, W., Raabe, A., and Redl, H. (2004). GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 21, 1553-61.

23. Diaz-Arrastia, R., Wang, K. K., Papa, L., Sorani, M. D., Yue, J. K., Puccio, A. M., McMahon, P. J., Inoue, T., Yuh, E. L., Lingsma, H. F., Maas, A. I., Valadka, A. B., Okonkwo, D. O., Manley, G. T., and TRACK-TBI Investigators. (2014). Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 31, 19-25.

24. Takala, R. S., Posti, J. P., Runtti, H., Newcombe, V. F., Outtrim, J., Katila, A. J., Frantzen, J., Ala-Seppala, H., Kyllonen, A., Maanpaa, H. R., Tallus, J., Hossain, M. I., Coles, J. P., Hutchinson, P., van Gils, M., Menon, D. K., and Tenovuo, O. (2015). Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 as Outcome Predictors in Traumatic Brain Injury. World Neurosurg 87, 8-20.

25. Kou, Z., Gattu, R., Kobeissy, F., Welch, R. D., O'Neil, BJ., Woodard, J. L., Ayaz, S. I, Kulek, A., Kas-Shamoun, R., Mika, V., Zuk, C., Tomasello, F., and Mondello, S. (2013). Combining biochemical and imaging markers to improve diagnosis and characterization of mild traumatic brain injury in the acute setting: results from a pilot study. PLoS One 8, e 80296.

26. Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., Shimshek, D. R., Neumann, U., Kahle, P. J., Staufenbiel, M., Neumann, M., Maetzler, W., Kuhle, J., and Jucker, M. (2016). Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91, 56-66.

27. Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q, Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., and Alzheimer’s Disease Neuroimaging Initiative. (2016). Alzheimer’s Disease Neuroimaging Initiative.  Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression.  JAMA Neurol 73, 60-67.

28. Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., Rosengren, L., Schott, J. M., Blennow, K., Eriksdotter, M., and Zetterberg, H. (2014).  CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.  Neurology 83, 1945-1953.

29. Shahim, P., Gren, M., Liman, V., Andreasson, U., Norgren, N., Tegner, Y., Mattsson. N., Andreasen, N., Öst, M., Zetterberg, H., Nellgård, B., and Blennow K (2016). Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 6, 36791.

30. Shahim, P., Zetterberg, H., Tegner, Y., and Blennow, K. (2017). Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788-1794.

31. Shahim, P., Tegner, Y., Gustafsson, B., Gren, M., Ärlig, J., Olsson, M., Lehto, N., Engström, Å., Höglund, K., Portelius, E., Zetterberg, H., and  Blennow, K. (2016). Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurol 73, 1308-1315

32. Posti, J. P., Takala, R. S., Runtti, H., Newcombe, V. F., Outtrim, J., Katila, A. J., Frantzen, J., Ala-Seppala, H., Kyllonen, A., Maanpaa, H. R., Tallus, J., Hossain, M. I., Coles, J. P., Hutchinson, P., van Gils, M., Menon, D. K., and Tenovuo, O. (2016). The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury: Correlations With Clinical and Imaging Findings. Neurosurgery 79, 456-64.

33. Baker, S. P., O'Neill, B., Haddon, W. Jr., and Long, W. B. (1974). The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care, J Trauma 14, 187-196.

34. King, N. S., Crawford, S., Wenden, F. J., Moss. N. E., Wade. D. T., and Caldwell. F. E. (1997). Measurement of post-traumatic amnesia: how reliable is it? J Neurol Neurosurg Psychiatry 62, 38–42

35. Marshall, L. F., Marshall, S. B., Klauber, M. R. , Van Berkum Clark, M., Eisenberg, H., Jane, J. A., Luerssen, T. G., Marmarou, A., and Foulkes, M. A. (1992). The diagnosis of head injury requires a classification based on computed axial tomography. J Neurotrauma 9 Suppl 1:S287-92.

36. Wilson, J. T., Pettigrew, L. E., and Teasdale, G. M. (1998). Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 15, 573-85.

37. King, N., Crawford, S., Wenden, F., Moss, N., and Wade, D. (1995). The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability. J Neurology 242, 587-592.

38. Xavier, Robin., Natacha, Turck., Alexandre, Hainard., Natalia, Tiberti., Frédérique, Lisacek., Jean-Charles, Sanchez., and Markus, Müller. (2013). PanelomiX: A threshold-based algorithm to create panels of biomarkers. Translational Proteomics 1, 57-64.

39. Lumpkins, K. M., Bochicchio, G. V., Keledjian, K., Simard, J. M., McCunn, M., and Scalea, T. (2008). Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma 65, 778-82; discussion 782-4.

40. Wiesmann, M., Steinmeier, E., Magerkurth, O., Linn, J., Gottmann, D., and Missler, U. (2010). Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 121, 178-85.

41. McMahon, PJ., Panczykowski, D. M, Yue, J. K, Puccio, A. M, Inoue, T., Sorani, M. D., Lingsma, H. F., Maas, A. I., Valadka, A. B., Yuh, E. L., Mukherjee, P., Manley, G. T., Okonkwo, D. O., and TRACK-TBI Investigators. (2015). Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J Neurotrauma 32, 527-33.

42. Metting, Z., Wilczak, N., Rodiger, L. A., Schaaf, J. M., and van der Naalt, J. (2012). GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology 78, 1428-33.

43. Thelin, E. P, Zeiler, F. A., Ercole, A., Mondello, S., Büki, A., Bellander, B. M., Helmy, A., Menon, D. K., and Nelson, D. W (2017). Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review. [Front Neurol.](https://www.ncbi.nlm.nih.gov/pubmed/28717351) 8, 300.

44. Halford, J., Shen, S., Itamura, K., Levine, J., Chong, A.C., Czerwieniec, G., Glenn, T.C., Hovda, D.A., Vespa, P., Bullock, R., Dietrich, W.D., Mondello, S., Loo, J.A., and Wanner, I.B. (2017). New astroglial inury-defined biomarkers for neurotrauma assessment. J Cereb Blood Flow Metab 37, 3278-3299.

45. van der Naalt, J., Timmerman, M. E., de Koning, M.E., van der Horn, H. J., Scheenen, M. E., Jacobs, B., Hageman, G., Yilmaz, T., Roks, G., and Spikman JM (2017). Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol 16, 532-540.

46. Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., and Zetterberg H. (2016). Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54, 1655-61.

47. van der Naalt, J., van Zomeren, A.H., Sluiter, W.J., and Minderhoud, J.M. (1999). One year outcome in mild to moderate head inury: the predictive value of acute inury characteristics related to complaints and return to work. J Neurol Neurosurg Psychiatry 66, 207-13.

48. Mondello, S., Sorinola, A., Czeiter, E., Vamos, Z., Amrein, K., Synnot, A., Donoghue, E., Sandor, J., Wang, K.K.W., Diaz-Arrastia, R., Steyeberg, E.W., Menon, D.K., Maas, A.I.R, and Buki, A. (2018). Blood-based protein biomarkers for the management of traumatic brain inuries in adults presenting to emergency departments with mild brain inury: a living systematic review and meta-analysis. J Neurotrauma. Epub ahead of print.